EV71 vaccine containing adjuvant combination

A technology of EV71 and EV71-VLP, applied in the field of biomedicine, can solve problems such as weak immunogenicity and poor immune response, and achieve the effect of reducing morbidity, severe disease and death cases

Inactive Publication Date: 2018-11-23
SOUTH CHINA UNITED VACCINE INST
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, current studies have shown that compared with EV71 whole virus, the immunogenicity of EV71-VLP is relatively weak, and effective adjuvant assistance is often required to elicit an ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • EV71 vaccine containing adjuvant combination
  • EV71 vaccine containing adjuvant combination
  • EV71 vaccine containing adjuvant combination

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Embodiment 1 A kind of EV71 vaccine containing adjuvant combination

[0033] Vaccine preparation method of the present invention

[0034] Reference patent: Preparation method of ZL201310697541.X to prepare EV71-VLP;

[0035] The content of PolyI:C (polyinosinic acid-polycytidylic acid) in each dose of vaccine is 50 μg, the content of EV71-VLP (EV71 virus-like particle) is 1 μg, and aluminum hydroxide adjuvant (the weight of aluminum element is 100 μg) . The EV71 antigen is EV71-VLP expressed using the baculovirus vector system.

Embodiment 2

[0036] Embodiment 2 A kind of EV71 vaccine containing adjuvant combination

[0037] Vaccine preparation method of the present invention

[0038] Reference patent: Preparation method of ZL201310697541.X to prepare EV71-VLP;

[0039] The content of PolyI:C (polyinosinic acid-polycytidylic acid) in each dose of vaccine is 20 μg, the content of EV71-VLP (EV71 virus-like particle) is 1 μg, and aluminum hydroxide adjuvant (the weight of aluminum element is 50 μg) . The EV71 antigen is EV71-VLP expressed using the baculovirus vector system.

Embodiment 3

[0040] Embodiment 3 A kind of EV71 vaccine containing adjuvant combination

[0041] Vaccine preparation method of the present invention

[0042] Reference patent: Preparation method of ZL201310697541.X to prepare EV71-VLP;

[0043] The content of PolyI:C (polyinosinic acid-polycytidylic acid) in each dose of vaccine is 80 μg, the content of EV71-VLP (EV71 virus-like particle) is 1 μg, and aluminum hydroxide adjuvant (the weight of aluminum element is 150 μg) . The EV71 antigen is EV71-VLP expressed using the baculovirus vector system.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an EV71 vaccine containing an adjuvant combination. The EV71 vaccine is prepared from the following main components: EV71 virus-like particles (EV71-VLPs), an aluminum adjuvantand polyinosinic acid cytidylic acid (poly I: C). The immunogenicity of the EV71 protein vaccine provided by the invention is superior to that of monophosphate lipids A (MPLA), Al or a poly I: C adjuvant vaccine which is singly used currently; the EV71 vaccine not only can well induce humoral immune response with antigen specificity, but also can induce high-level cellular immune response; the vaccine can effectively prevent related diseases caused by EV71 virus infection.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to an EV71 vaccine containing an adjuvant combination. Background technique [0002] According to the reported molecular epidemiological studies on EV71, enterovirus 71 (EV71) is the main cause of severe and fatal HFMD, which can cause 80% severe disease and 93% mortality. Due to the lack of effective specific drugs for the treatment of hand, foot and mouth disease, vaccination has become the most important means of preventing and controlling the outbreak and widespread epidemic of this kind of disease. Vaccines developed around HFMD mainly include whole virus inactivated vaccines, EV71-VLP vaccines, vector vaccines and VP1 recombinant protein vaccines, etc. Among them, whole virus inactivated vaccines are the fastest-growing and fastest-growing. The whole virus vaccine is put into use. [0003] Virus-like particles (VLPs) are empty shell structures that do not contain viral...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/15A61K39/39A61P31/14
CPCA61K39/12A61K39/39A61K2039/55505A61K2039/55511A61P31/14C12N2770/32334
Inventor 彭涛许煜华马书智黄杨波陈丽云丁东郑燕萍苏文瀚陈凤英
Owner SOUTH CHINA UNITED VACCINE INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap